Pre-made Bentracimab benchmark antibody ( Whole mAb, anti-AR-C124910XX therapeutic antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-059
Pre-Made Bentracimab biosimilar, Whole Mab: Anti-AR-C124910XX therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Bentracimab is a monoclonal antibody medication which has been shown in phase one and two clinical trials to function as a reversal agent for the anti-blood clotting drug ticagrelor (which acts as a P2Y12 inhibitor and is sold under the brand name Brilinta among others). It is under investigation for use in major, life-threatening bleeding in patients being treated with ticagrelor. It is not commercially available.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Bentracimab biosimilar, Whole Mab: Anti-AR-C124910XX therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||5alb:HL|
|99% SI Structure||None|
|95-98% SI Structure||5alc:HL|
|Conditions Active||Haemorrhage (reversal of effects of ticagrelor)|